LEGN.US

Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its loss also narrowed sharply to $18 million from $199 million. Most of its revenue came from sales of Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy to treat cancer.

“Momentum for Carvykti is growing,” said Legend CEO Huang Ying, commenting on the drug that has become Legend’s primary revenue source since its approval by the FDA in the U.S. in 2022. “We look forward to starting commercial production at our Obelisc facility in Belgium later this year in order to meet the growing demand, and we remain laser-focused on increasing our manufacturing capacity.”

Recent Articles

BRIEF: JST jumps in Hong Kong trading debut

Shares of e-commerce software as a service (SaaS) enterprise resource planning (ERP) provider JST Group Co. Ltd. (6687.HK) opened 24.2% higher in their Hong Kong trading debut on Tuesday, and…
ECARX makes infrastructure

BRIEF: CATL extends lead with 40% third-quarter profit growth

Leading lithium battery maker  Contemporary Amperex Technology Co. Ltd. (3750.HK; 300750.SZ)(CATL) reported on Monday its revenue rose 12.9% year-over-year to 104.2 billion yuan ($14.63 billion) in the third-quarter, while its…